Specifically, we sought to determine the impact of transient overexpression of GATA3 and FOXA1, individually and in combination with each other, and in both the absence and presence of the PPARɣ agonist rosiglitazone, on the expression of markers of luminal (FGFR3 and KRT20) and basal (EGFR and KRT6) bladder cancer. This evidence concerns the gene FGFR3 and urinary bladder cancer.